Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1992 Nov;55(11):1009–1013. doi: 10.1136/jnnp.55.11.1009

The dopaminergic response in multiple system atrophy.

A J Hughes 1, C Colosimo 1, B Kleedorfer 1, S E Daniel 1, A J Lees 1
PMCID: PMC1015283  PMID: 1469394

Abstract

Fifteen of 23 pathologically confirmed cases of multiple system atrophy (MSA) showed some initial response to levodopa and eight of these remained at least partially responsive at the time of death. Eleven developed motor oscillations, and drug-induced dyskinesias, often involving the face and jaw, were also seen in 11 cases. Acute levodopa and apomorphine challenges were administered to 11 patients with clinical MSA who were considered levodopa responsive. A short duration relatively small amplitude response with associated dyskinesias occurred in six and a further three developed dyskinesias without any motor response. Following levodopa withdrawal, a delayed deterioration occurred after three to six days in six patients, five of whom had shown no short duration motor response to the acute challenges. The occurrence of levodopa-induced dyskinesias without a concomitant motor response and delayed deterioration several days after levodopa withdrawal may be more typical of patients with MSA than Parkinson's disease.

Full text

PDF
1009

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau A., Roy M. Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease. Neurology. 1976 May;26(5):399–404. doi: 10.1212/wnl.26.5.399. [DOI] [PubMed] [Google Scholar]
  2. Boudin G., Guillard A., Mikol J., Galle P. Dégénérescence striato-nigrique. A propos de l'étude clinique, thérapeutique et anatomique de 2 cas. Rev Neurol (Paris) 1976 Feb;132(2):137–156. [PubMed] [Google Scholar]
  3. Fearnley J. M., Lees A. J. Striatonigral degeneration. A clinicopathological study. Brain. 1990 Dec;113(Pt 6):1823–1842. doi: 10.1093/brain/113.6.1823. [DOI] [PubMed] [Google Scholar]
  4. Feve J. R., Mussini J. M., Mathé J. F., Cler J. M., Nomballais M. F. Dégénérescence striato-nigrique. Etude clinique et anatomique d'un cas ayant réagi très favorablement à la L-Dopa. Rev Neurol (Paris) 1977 Apr;133(4):271–278. [PubMed] [Google Scholar]
  5. Goetz C. G., Tanner C. M., Klawans H. L. The pharmacology of olivopontocerebellar atrophy. Adv Neurol. 1984;41:143–148. [PubMed] [Google Scholar]
  6. Goetz C. G., Tanner C. M., Nausieda P. A. Weekly drug holiday in Parkinson disease. Neurology. 1981 Nov;31(11):1460–1462. doi: 10.1212/wnl.31.11.1460. [DOI] [PubMed] [Google Scholar]
  7. Gosset A., Pellissier J. F., Delpuech F., Khalil R. Dégénérescence striato-nigrique associée à une atrophie olivo-ponto-cérébelleuse. Etude anatomo-clinique de trois cas. Discussion nosologique. Rev Neurol (Paris) 1983;139(2):125–139. [PubMed] [Google Scholar]
  8. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hughes A. J., Lees A. J., Stern G. M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990 Jul 7;336(8706):32–34. doi: 10.1016/0140-6736(90)91531-e. [DOI] [PubMed] [Google Scholar]
  10. Izumi K., Inoue N., Shirabe T., Miyazaki T., Kuroiwa Y. Failed levodopa therapy in striato-nigral degeneration. Lancet. 1971 Jun 26;1(7713):1355–1355. doi: 10.1016/s0140-6736(71)91914-3. [DOI] [PubMed] [Google Scholar]
  11. Kempster P. A., Frankel J. P., Bovingdon M., Webster R., Lees A. J., Stern G. M. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):718–723. doi: 10.1136/jnnp.52.6.718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klawans H. L., Goetz C. G., Tanner C. M., Nausieda P. A., Weiner W. J. Levodopa-free periods ("drug holidays") in the management of parkinsonism. Adv Neurol. 1983;37:33–43. [PubMed] [Google Scholar]
  13. Koller W. C. Alternate day levodopa therapy in parkinsonism. Neurology. 1982 Mar;32(3):324–326. doi: 10.1212/wnl.32.3.324. [DOI] [PubMed] [Google Scholar]
  14. Lang A. E., Birnbaum A., Blair R. D., Kierans C. Levodopa dose-related fluctuations in presumed olivopontocerebellar atrophy. Mov Disord. 1986;1(2):93–102. doi: 10.1002/mds.870010203. [DOI] [PubMed] [Google Scholar]
  15. Lang A. E., Meadows J. C., Parkes J. D., Marsden C. D. Early onset of the "on-off" phenomenon in children with symptomatic Parkinsonism. J Neurol Neurosurg Psychiatry. 1982 Sep;45(9):823–825. doi: 10.1136/jnnp.45.9.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mouradian M. M., Heuser I. J., Baronti F., Fabbrini G., Juncos J. L., Chase T. N. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol. 1989 May;25(5):523–526. doi: 10.1002/ana.410250521. [DOI] [PubMed] [Google Scholar]
  17. Muenter M. D., Tyce G. M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc. 1971 Apr;46(4):231–239. [PubMed] [Google Scholar]
  18. Murrow R. W., Schweiger G. D., Kepes J. J., Koller W. C. Parkinsonism due to a basal ganglia lacunar state: clinicopathologic correlation. Neurology. 1990 Jun;40(6):897–900. doi: 10.1212/wnl.40.6.897. [DOI] [PubMed] [Google Scholar]
  19. Ogasahara S., Nishikawa Y., Takahashi M., Wada K., Nakamura Y., Yorifuji S., Tarui S. Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease. J Neurol Sci. 1984 Nov-Dec;66(2-3):151–163. doi: 10.1016/0022-510x(84)90003-0. [DOI] [PubMed] [Google Scholar]
  20. Quinn N. Multiple system atrophy--the nature of the beast. J Neurol Neurosurg Psychiatry. 1989 Jun;Suppl:78–89. doi: 10.1136/jnnp.52.suppl.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rajput A. H., Kazi K. H., Rozdilsky B. Striatonigral degeneration response to levodopa therapy. J Neurol Sci. 1972 Jul;16(3):331–341. doi: 10.1016/0022-510x(72)90196-7. [DOI] [PubMed] [Google Scholar]
  22. Rajput A. H., Rozdilsky B., Rajput A., Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol. 1990 Dec;13(6):553–558. doi: 10.1097/00002826-199012000-00007. [DOI] [PubMed] [Google Scholar]
  23. Sharpe J. A., Rewcastle N. B., Lloyd K. G., Hornykiewicz O., Hill M., Tasker R. R. Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. J Neurol Sci. 1973 Jul;19(3):275–286. doi: 10.1016/0022-510x(73)90091-9. [DOI] [PubMed] [Google Scholar]
  24. Trotter J. L. Striatonigral degeneration, Alzheimer's disease, and inflammatory changes. Neurology. 1973 Nov;23(11):1211–1216. doi: 10.1212/wnl.23.11.1211. [DOI] [PubMed] [Google Scholar]
  25. Ward C. D., Gibb W. R. Research diagnostic criteria for Parkinson's disease. Adv Neurol. 1990;53:245–249. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES